293 filings
Page 3 of 15
8-K
rhg2lwr1hvonikd6eggn
21 Jul 21
Other Events
5:17pm
8-K
182ogvk9u37z 2hxcx
22 Jun 21
Acasti Pharma Provides Fiscal 2021 Year-End Business Update
7:00am
8-K
wg0g9q4hcdrm9abe
17 May 21
Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance
7:11am
8-K
tcjpyv nub
7 May 21
Entry into a Material Definitive Agreement
7:09am
8-K
753r2ab
9 Mar 21
Acasti Pharma Provides Update on Recent Financing Activities
12:00am
8-K
hb0228h9umje4run9ys2
9 Feb 21
Acasti Pharma Announces Results for Third Quarter of Fiscal 2021
4:35pm
8-K
mgdw2lcac w1
27 Jan 21
Acasti Pharma Provides Update on Recent Financing Activities
7:35am
8-K
n2kt4mb0ikxus
4 Dec 20
Other Events
8:00am
8-K
zgfq3u1c1 4ef
16 Nov 20
Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2021
7:05am
8-K
19f21v3w
7 Oct 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:30am
8-K
k1p0zs045x8z9dwy
2 Oct 20
Amendments to Articles of Incorporation or Bylaws
3:39pm
8-K
mltfxs25
29 Sep 20
Acasti Announces Review Process of Strategic Alternatives
8:19am
8-K
hohss1 32pniufds7yyh
17 Sep 20
Acasti Appoints Seasoned Executive Brian D. Ford CPA-CA as Chief Financial Officer
9:54pm
8-K
48ve602occ
11 Sep 20
Acasti Announces Filing and Mailing of Information Circular and Change in Record Date
7:00am
8-K
3kc4k3
31 Aug 20
Acasti Pharma Reports Topline Triglyceride Results from Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia
4:05pm
8-K
2ospc467ef
13 Aug 20
Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2021
8:30am
8-K
0t8n8sh
31 Jul 20
Regulation FD Disclosure
4:05pm
8-K
6nh5p 8jtwhq7w0ypux
30 Jun 20
Entry into a Material Definitive Agreement
9:01am
8-K
7honq
29 Jun 20
Acasti Pharma Provides Fiscal 2020 Year-End Business Update
12:50pm
8-K
yryqv5
19 Jun 20
Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing Package
9:09am